About Us

Home » About Us » overview


Fortress Biotech ("Fortress" or "the Company") is an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential clinical-stage assets. The company has over 25 programs in clinical development at Fortress, at its majority-owned and majority-controlled subsidiaries and at entities it founded and in which it holds significant minority ownership positions.  Such product candidates span six large-market therapeutic areas, including oncology, rare diseases and gene therapy, which allow it to create value while mitigating risk for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., City of Hope, Fred Hutchinson Cancer Research Center, InvaGen Pharmaceuticals, Inc. (a subsidiary of Cipla Limited), St. Jude Children’s Research Hospital, and UCL Business PLC. 

Business Strategy

Our overriding business strategy is to create a portfolio of marketed products and products under development that provide us and our shareholders a diversified long-term revenue stream.  We plan to maintain an economic interest in our development programs through royalty rights and will have equity stakes in products that are developed through the Fortress Companies.  Each of the Fortress Companies will have dedicated management teams as well as a management services arrangement with the Company to ensure consistent management and drug development quality across the Fortress Companies.

We are therapeutic area agnostic, which provides maximum flexibility, allowing us to invest in a broad array of new technologies with clinical and commercial potential.  Our streamlined management structure and extensive experience in structuring deals enables us to quickly take advantage of time-sensitive opportunities and provides us with a range of options to select what we believe is the most advantageous corporate or financial structure for the development of each product candidate.  Over time, our novel approach is also expected to provide opportunities to achieve synergies across the Fortress Companies.  We encourage collaboration and sense of team work among employees of the Fortress Companies.  We believe leveraging skills and expertise from the Company and each of the Fortress Companies will accelerate drug development and promote best practices.